Cargando…

PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA

Detalles Bibliográficos
Autores principales:	Mutsaers, Pim G. N. J., Abramson, Jeremy S., Namuduri, Manjusha, LI, Jingjin, Sophos, Nickolas A., Zhu, Min, Brouwer-Visser, Jurriaan, Mohamed, Hesham, Chaudhry, Aafia, Davies, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428821/ http://dx.doi.org/10.1097/01.HS9.0000976032.70825.65

Ejemplares similares

PB2366: TRIAL IN PROGRESS: PHASE 1 TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF ODRONEXTAMAB IN COMBINATION WITH CEMIPLIMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Segura, Cecilia Carmen Carpio, et al.
Publicado: (2023)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
por: Tessoulin, Benoit, et al.
Publicado: (2023)

PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
por: Novelli, Silvana, et al.
Publicado: (2023)

PB2267: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)
por: Luminari, Stefano, et al.
Publicado: (2023)

PB2343: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS STANDARD OF CARE THERAPY IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (OLYMPIA-4)
por: Hawkes, Eliza A., et al.
Publicado: (2023)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
por: Vitolo, Umberto, et al.
Publicado: (2023)

PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY
por: Cho, Seok-Goo, et al.
Publicado: (2023)

Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
por: Weinstock, Matt, et al.
Publicado: (2022)

PB2328: CHRONIC LYMPHATIC LEUKAEMIA (CLL) ASSOCIATED TO ACQUIRED FACTOR V INHIBITOR. A CASE REPORT.
por: Porro Camarero, A., et al.
Publicado: (2022)

P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
por: Walewski, Jan, et al.
Publicado: (2023)

P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
por: Taszner, Michał, et al.
Publicado: (2023)

REGN-EB3: First Approval
por: Markham, Anthony
Publicado: (2021)

PB2357: TRIAL IN PROGRESS: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH SYSTEMIC THERAPY FROM REAL-WORLD EXPERIENCE (ORCHID)
por: Thieblemont, Catherine, et al.
Publicado: (2023)

PB2281: TRIAL IN PROGRESS: FOLLICULAR LYMPHOMA OUTCOMES IN RELAPSED/REFRACTORY PATIENTS TREATED WITH SYSTEMIC THERAPY IN A REAL-WORLD ASSESSMENT (FLORA)
por: Damaj, Gandhi Laurent, et al.
Publicado: (2023)

Athena’s Reply
por: V, Raveenthiran
Publicado: (2015)

Athena's Pages
por: Raveenthiran, V
Publicado: (2012)

Le régne de l'esprit malin
por: Ramuz, C. F. (Charles Ferdinand), 1878-1947
Publicado: (1946)

PReS-FINAL-2328: Developing and validating the new severity score for FMF
por: Demirkaya, E, et al.
Publicado: (2013)

The ATHENA positron accumulator
por: van der Werf, D P, et al.
Publicado: (2002)

HLT Validation of Athena
por: Bee, C P, et al.
Publicado: (2002)

ATHENA - Ready to go!
Publicado: (2001)

The ATHENA antihydrogen detector
por: Amsler, C
Publicado: (2001)

The ATHENA antihydrogen experiment
por: Fine, K S, et al.
Publicado: (1999)

The ATHENA Antihydrogen Apparatus
por: Amoretti, M, et al.
Publicado: (2003)

Results from ATHENA
por: Rotondi, Alberto, et al.
Publicado: (2006)

Protonium production in ATHENA
por: Venturelli, L, et al.
Publicado: (2007)

The ATHENA experiment for the study of antihydrogen
por: Amsler, C, et al.
Publicado: (2014)

Athena Pile-Up Requirements
por: Luehring, F C
Publicado: (2001)

Antihydrogen production in the ATHENA experiment
por: CERN. Geneva
Publicado: (2003)

ATHENA: an actual antihydrogen annihilation
Publicado: (2002)

AthenaMT: a retrospective
por: Snyder, Scott
Publicado: (2023)

Progress Report on the ATHENA Experiment
por: Bowe, Paul, et al.
Publicado: (2003)

Antihydrogen production mechanisms in ATHENA
por: Bonomi, G, et al.
Publicado: (2005)

Development of the ATHENA vertex detector
por: Riedler, P
Publicado: (2000)

Progress Report on the ATHENA experiment
por: Landua, Rolf, et al.
Publicado: (2004)

Recent Results of the Athena Collaboration
por: Rotondi, Alberto, et al.
Publicado: (2006)

Athena’s Pages on Neonatal Appendicitis
por: Raghavendra Prasad, G
Publicado: (2015)

Loss of interleukin-1 beta is not protective in the lupus-prone NZM2328 mouse model
por: Loftus, Shannon N., et al.
Publicado: (2023)

2328. COVID-19 and CLABSI: Riding the Pandemic Waves with an Active Infection Prevention Intervention
por: Thyagarajan, Rama, et al.
Publicado: (2023)

Un « @-CPLF » sous le règne de la COVID-19
por: Schlemmer, F.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_afsti6dpseqqeec913rt1cvlr1